Data Abstraction Form:

Investigation of Mucormycosis Disease among Bone Marrow Transplant Patients

Initials:	
Case #:	
Medical Record #:	
Date of Birth:	
Reviewers Initials:	
Review Date:	

Case of Mucormycosis Infection of Interest

Bone marrow transplant patients with stays in unit 41 and 42 with any presentation of a mucormycosal infection excluding gastrointestinal

WITH

Histopathological or cytopathological examination showing hyphae from needle aspiration or biopsy specimen with evidence of associated tissue damage (either microscopically or as an infiltrate or lesion by imaging)

OR

Positive culture result for a sample obtained by sterile procedure from normally sterile and clinically or radiologically abnormal site consistent with mucormycosal infection.

Matched Controls

Bone marrow transplant patients (Preferred) with stays in unit 41 and 42:

- a date of birth is within five years of the matched mucormycosis case's birthday
- with matched hematologic malignancy (See section II)

Other major risk factors we will assess for and enough controls present, we can consider matching for diabetes status, diabetic ketoacidosis, blood iron overload condition, chronic high-dose corticosteroids use. If necessary we can also expand the control group to hematopoietic stem cell transplant from unit 41, or from unit 41 and 42.

Public reporting burden of this collection of information is estimated to average 90 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

Case-Case Abstraction Form

History of stem cell transplant

Section I: Demographic and Admission Data 1. Age at diagnosis (years): ____ 2. Gender: _____(0= Male, 1= Female) 3. Race (Select all that apply): (0=white/Caucasian, 1=black/African-American, 2=Asian, 3=American Indian/Alaskan, 4=Hawaiian/Pacific Islander, 5=not known) Ethnicity: _____(0=not Hispanic, 1=Hispanic, 2=not known) County: ____ State: _____ Phone #: Date of admission (mm/dd/yy): Admit diagnosis: ___ Section II: Underlying Medical Conditions and Risk Factors (at time of admission or before onsets, check all that apply) 9. General Medical Conditions: None Bone Marrow Transplant Other hematopoietic stem cell transplant Diabetes [not Diabetic Ketoacidosis (DKA)] Last Hemoglobin A1C level _____ Diabetic Ketoacidosis (DKA) during stay on unit Hemochromatosis Thalassemia Transfusion-induced iron overload in the 14 days before or during say on unit ___ Iron overload for any other reason and/or iron chelation therapy within 14 days prior to exposure to the unit (Desferrioxamine therapy) None 10. Immunocompromised State: Solid organ transplant (ever) renal liver lung heart other (specify) If transplant recipient, date of most recent transplant (mm/dd/yy): ____/___/ Solid tumor malignancy (specify type): _____ If history of solid tumor, on or had been on chemotx in the 14 days before culture? Yes No Unknown

Neutropenia (< 500 neutrophils per mm³) within 14 days prior to onset (or admission?)

Total number of neutropenic days within 14 day period:ororOr
Systemic corticosteroids at avg dose ≥0.3 mg/kg/day prednisone (or equivalent) for > 3 weeks
Chronic Granulomatous Disease
Other(specify)
Hematologic malignancy
Leukemia
Acute myeloid leukemia (AML) (e.g. M0-M7)
Chronic myeloid leukemia (CML) (e.g. Chronic phase, Accelerated phase, Blast crisis)
Acute lymphocytic leukemia (ALL) (e.g. L1-L3)
Chronic lymphocytic leukemia (CLL) (e.g. B cell origin, T cell origin, Adult T cell leukemia, Sezary
syndrome, Unclassified)
Hodgkin's disease (e.g. Lymphocyte predominant, Lymphocyte rich, Nodular sclerosis, Hairy cell leukemia,
Mixed cellularity, Lymphocyte depleted, Large, granular lymphocyte leukemia)
Non-Hodgkin's lymphoma (e.g. B cell origin, T cell origin)
Aplastic anemia
Multiple myeloma
Myelodysplastic syndrome (e.g. RA, RARS, RAEB-1, RAEB-2, RCMD, RCMD/RS, 5q syndrome, CMML)
Sickle cell anemia
Other
If history of heme malignancy, on or had been on chemotx in the 14 days before culture?
Yes No Unknown
Graft-versus-host disease:
Acute; if yes, record grade (I-IV)
Chronic; if yes, check one: limited extensive unknown
None
Unknown

Section III: Location

11. Did this patient hav	e any prior INPATIEN	$oldsymbol{\Gamma}$ hospitalizations wi	ithin 30 days prior to the curr	ent admission?	
(Include ALL hospitaliz	ations, including those n	ot at Hospital A)			
Yes (fill out table below, with most recent hospital admissions) No Unknown					
Facility Name	Admission Dates	Ward/Bed	First date at location	Last date at location	
	(mm/dd/yy)-	(complete for each			
	(mm/dd/yy)	location)			
			Unk	Unk	
			Unk		
				Unk	
Other acute care Rehabilitation Other (specify): Unknown 13. Room history during	ubacute care facility hospital g current admission:				
Ward/Room	First date at location		Last date at location (or	· Unk)	
		Unk		Unk	
		Unk		Unk	
		Unk		Unk	
		Unk		Unk	

Culture Date	Specimen Site/Type	Organism
(mm/dd/yy)	(blood, sputum, pleural fl	luid,
· 33/	CSF, etc)	
. Did patient have a pos	itive Mucor pathology finding?	Yes No Unknown
If yes, please complete	e table:	
Date (mm/dd/yy)	Anatomical site	Organism/Description of Fungal Elements
. If patient had a head (CT, please list date:	
Cavernous sinus th	rombosis	
Changes to the orb	it	
Semiacute right from	ontal lobe infarct	
Diffuse sinusitis		
Describe other finding	s:	
. If patient had a head N	ARI, please list date:	
Cavernous sinus th	rombosis	
Changes to the orb	it	
Semiacute right from	ontal lobe infarct	
Diffuse sinusitis		
Describe other finding	s:	
. Does the patient have	a history of positive cultures for M	Mucor? Yes No Unknown
If yes, date of previous	s culture :	
n V: Medications/Proce		
·	•	including chemotherapy) within 30 days of the index culture
date? Yes N	_	
If yes, please list:	1)	
	2)	
	3)	
	4)	
	5)	

Antifungal drug	Given?	Total days of therapy in 30- day period	Date of last dose prior to firs culture (mm/dd/yy)
Amphotericin B	Yes No		
(Polyene Antifungal)	Unknown		Unk
Fungizone,			
(Lipid-based Polyene Antifungal)			
Amphotec Abelcet			
AmBisome Amphocil,			
ABLC ABCD			
Anidulafungin (Eraxis) (an	Yes		
Echinocandin)	No Unknown		Unk
Caspofungin (Cancidas) (an	Yes		
Echinocandin)	No Unknown		Unk
Fluconazole (Diflucan) (an Azole)	Yes		
	No		Unk
Flucytosine (5FC) (a Nucleoside	Unknown Yes		
Analog Antifungal)	No		Unk
Micafungin (Mycamine) (an	Unknown Yes		
Echinocandin)	No No		Unk
Posaconazole (Noxafil) (an Azole)	Unknown Yes		
(No		Unk
Itraconazole (Sporanox) (an Azole)	Unknown Yes		
araconazore (oporanon) (un rizore)	No		Unk
Voriconazole (Vfend) (a Triazole)	Unknown Yes		
volicoliazole (vielid) (a iliazole)	No		T.T1-
	Unknown		Unk
1. Mars the matter that have 12. West	NI. TIL		
1. Was the patient intubated? Yes		nown	
If yes, complete the following question		TI Calab	
a. Where was the patient intub		.u, field):	
	ral Nasal		
c. List dates of intubation:		ubation? Prior	After

	a.	If yes,	date of trach	eostomy?/			
	b.	If yes,	did index cul	ture date occur prior	to or after tr	acheostomy? Prior	After
23.	Did the Yes e.	If yes,		own		Nebulized meds (SV	
			CPAP/BIPAP	Other		None	Unknown
		i.	. If 'yes' to	SVN or MDI, fill in t Drug		ow: Tode of Administration (S	VN or MDI)
				Diug	141	ode of Administration (3	VIV OI WIDI)
24.				ares within 30 days p	orior to the in	dex culture date?	•
	Yes						
	11 yes, p		neck all that a	рргу:			
			oracentesis			Date: // /	
		Bro	onchoscopy			Date:	
						Date://	
						Date://	
		Th	oracotomy (C	Chest tube insertion)		Date://	
		En	doscopy			Date:///	
		Tra	ansesophagea	l echocardiogram		Date:///	
		Su	rgery (1)			Date:///	
						OR #:	
			(2)			Date:///	
						OR #:	
		Per	rcutaneous/in	terventional radiolog	y procedure:		
			fy) Date: 🔲				
		U Otl	her		_(specify)	Date:///	

Sec	tion VI: Symptoms					
25.	5. Was the onset of symptoms more chronic, over the course of several weeks? Yes Unknown					
26.	. Manifested as an acute sinus infection? Yes Unknown					
27.	Nasal congestion? Yes No Unknown					
28.	Fever? Yes No Unknow	n				
29.	Headache? Yes No Unk	nown				
30.	Facial pain? Yes No Unl	known				
31.	Tinnitus? Yes No Unkno	own				
32.	Reddish and swollen skin over nose an	nd sinuses? Yes	No Unkno	own		
33.	Periorbital edema and erythema (Redd	ish and swollen ski	n around the eye)?	Yes No Unknown		
34.	Ptosis of the eyelid? Yes No	Unknown				
35.	Visual problems? Yes No	Unknown				
36.	Edema and hypertrophy of the nasal tu	arbinates? Yes	No Unknow	vn		
37.	Edema and hypertrophy of the posterio	or pharynx? 🗌 Yes	No Unkn	own		
38.	Altered mental status? Yes No	o Unknown				
39.	Blindness of the eye? Yes No	Unknown				
40.	Dilated pupil? Yes No U	Jnknown				
41.	1. Nonreactive pupil? Yes No Unknown					
42.	2. Cavernous sinus thrombosis? Yes No Unknown					
43.	3. Evidence of spread to the brain? Yes Unknown					
44.	Spread to the orbits? Yes No	Unknown				
	Section VII: Treatment 45. Did the patient undergo debridment? Yes No Unknown					
46.	6. Myringotomy with insertion of a tympanostomy? Yes Unknown					
47.	Hyperbaric oxygen therapy (HBO)?	Yes No	Unknown			
48.	Did the patient undergo surgery for tre	atment (not diagno	sis) of rhinocerebral	mucormycosis?		
49.	Yes No Unknown					
50.	50. If yes, what was the name of the procedure? (e.g. Frontal lobectomy, Ethmoidectomy, Maxillary sinus antrostomy, Frontal sinusotomy, Sphenoidectomy)					
51.	51. Was the patient treated with an antifungal after the infection was diagnosed? Yes No Unknown					
	If yes, complete table:					
	Antifungal drug	Given?	Total days of	Date of last dose prior to first		
			therapy in 30- day period	culture (mm/dd/yy)		
Aı	nphotericin B	Yes	J <u>J</u>			
((Polyene Antifungal) No Unknown Unknown			Unk		
	Fungizone,					
	(Lipid-based Polyene Antifungal)					

Amphotec Abelcet					
AmBisome Amphocil,					
☐ ABLC ☐ ABCD					
Anidulafungin (Eraxis) (an	Yes				
Echinocandin)	Unknown	Unk			
Caspofungin (Cancidas) (an	Yes				
Echinocandin)	Unknown	Unk			
Fluconazole (Diflucan) (an Azole)	Yes				
	Unknown	Unk			
Flucytosine (5FC) (a Nucleoside	Yes				
Analog Antifungal)	Unknown	Unk			
Micafungin (Mycamine) (an	Yes				
Echinocandin)	Unknown	Unk			
Posaconazole (Noxafil) (an Azole)	Yes				
	Unknown	Unk			
Itraconazole (Sporanox) (an Azole)	Yes				
	☐ No ☐ Unknown	Unk			
Voriconazole (Vfend) (a Triazole)	Yes No				
	Unknown	Unk			
52. Renal indices monitored during therap					
53. Nephrotoxicity levels during treatment					
	o Unknown				
	nknown				
56. Deferiprone?					
Section VII: Outcomes	1				
57. Was infected sinus tissue or sinus tissue destruction visibly observed? Yes No Unknown					
58. Significant devitalized mucous membranes? Yes No Unknown					
59. Significant devitalized mucous membranes?					
60. Necrotic lesions in the:					
f. Nasal mucosa? Yes No Unknown					
h. Hard palate? Yes	g. Turbinates? Yes No Unknown h. Hard palate? Yes No Unknown				
61. Extension of the disease into the:					
Maxillary sinus? Yes	No Unknown				
52. Invasion of the surrounding vasculature?					
63. Spread into the cribriform plate or the orbital apex?					

64.	Did the patient require enucleation? Yes No Unknown
65.	Occlusion of the carotid artery, causing an internal carotid artery pseudoaneurysm?
	Yes No Unknown
66.	Infarction and necrosis of tissues in other structures?
	Other structures involved?
67.	Was patient diagnosed with rhinocerebral mucormycosis in the medical record?
	Yes Unknown Not applicable
68.	Date of discharge (mm/dd/yy)://
69.	Status at discharge:
	Alive Deceased Unknown
70.	If deceased, date of death:
71.	If patient is deceased, is death certificate available?
	Yes Unknown Not applicable
72.	If yes, is invasive fungal infection (IFI) listed as cause of death?
	Yes Unknown Not applicable
	If yes, is IFI listed as primary or secondary cause of death? Primary Secondary
73.	If patient is deceased, was an autopsy performed?
	Yes Unknown Not applicable
74.	If yes, was evidence of invasive fungal infection (IFI) present?
	Yes No Unknown Not applicable